脐血干细胞联合人参促分化合剂治疗失代偿期肝硬化疗效研究  

Umbilical Cord Blood Stem Cell Transplantation and Ginseng Promoting Differentiation Mixture in Patients with Decompensated Cirrhosis

作　　者：陈玉梅[1] 王丽华[1] 李炳茂[1] 孙建顺[1] 张丽贤[1] 杨彬[1] 

机构地区：[1]哈励逊国际和平医院消化内科,河北省衡水市053000

出　　处：《中国全科医学》2015年第2期211-214,共4页Chinese General Practice

基　　金：河北省中医药管理局科研基金项目(2012234)

摘　　要：目的探讨脐血干细胞联合人参促分化合剂治疗失代偿期肝硬化的疗效。方法选择2012年2月—2013年4月衡水市哈励逊国际和平医院消化内科确诊的失代偿期肝硬化患者30例,术前行常规保肝治疗,采用细胞分离技术从脐带血中提取干细胞,经肝固有动脉将干细胞悬液移植入肝脏。移植成功后给予人参促分化合剂辅助治疗,治疗14 d。治疗后第16周观察患者肝功能指标,包括ALT、AST、清蛋白(Alb)、总胆红素(TBi L)、凝血酶原活动度(PTA);治疗后第24周观察血清学纤维化指标,包括透明质酸(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PC-Ⅲ)、Ⅳ型胶原(Ⅳ-C);治疗后第24周行CT检查,观察肝脏影像学变化,包括肝脏最大截面积和肝脏平扫CT值。结果治疗后第16周,患者血浆ALT、AST、TBi L低于治疗前,Alb、PTA高于治疗前(P<0.05)。治疗后第24周,患者HA、PC-Ⅲ、Ⅳ-C、LN均低于治疗前(P<0.05)。治疗后第24周,患者肝脏最大截面积多于治疗前(P<0.05);治疗前后,肝脏平扫CT值比较,差异无统计学意义(P>0.05)。结论脐血干细胞联合人参促分化合剂可以改善失代偿期肝硬化患者肝功能,修复肝脏损伤,是临床治疗失代偿期肝硬化的一种有效措施。Objective To study the effect of umbilical cord blood stem cell transplantation（ UCBCT） and ginseng promoting differentiation mixture（GPDM）therapy on decompensated cirrhosis（DC）. Methods From February 2012 to April 2013,in Department of Gastroenterology,Harrison International Peace Hospital,30 DC patients underwent conventional liver protection therapy. Cell isolation technics was used to draw UCBC from umbilical cord blood（ UCB） and implanted UCBC suspension into the liver through arteria hepatica propria. After successful implantation,patients were given GPDM adjuvant therapy,14 d. We observed liver function indicators including ALT, AST, albumin （ Alb ）, total bilirubin （ TBiL）, prothrombin activity（ PTA） in weeks 16 after treatment,serum fibrosis markers including hyaluronic acid（ HA）,laminin （LN）,procollagen Ⅲ（PC - Ⅲ）,Ⅳ collagen（Ⅳ - C）in weeks 24 after treatment. In weeks 24 after treatment,patients underwent CT examination,the changes of liver imaging were observed including CT values of liver maximum cross - sectional area and liver plain scan. Results Plasma ALT,AST,TBiL were lower,Alb,PTA higher in weeks 16 after treatment than before treatment（P 〈 0. 05）,and HA,PC - Ⅲ,Ⅳ - C,LN lower,liver maximum cross - sectional area larger in weeks 24 after treatment than before treatment（P 〈 0. 05）. There was no significant difference in liver plain scan value between before and after treatment（P 〉 0. 05）. Conclusion UCBCT combined with GPDM,which can improve the liver function and repair liver damages in DC patients,is a effective clinical treatment of DC.

关 键 词：胎血 脐血干细胞移植 肝硬化 人参促分化合剂 

分 类 号：R657.31[医药卫生—外科学]